Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor + G-CSF for Stem Cell Mobilization in NHL
NCT01767714Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-Hodgkin lymphoma (NHL) comparing G-CSF + plerixafor with G-CSF + Placebo (2 arms). Primary endpoint: Number of patients who meet the target of ≥5 × 10^6 CD34+ cells/kg in 4 or fewer days of apheresis. Started Apr 2013; status: completed.
02
Drugs
plerixafor
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01767714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01767714.